Hua Haiying, Zhang Nan, Liu Dan, Song Lili, Liu Tuanbing, Li Shasha, Zhao Yongxing
Academy of Medical and Pharmaceutical Sciences.
Department of Pharmaceutics, School of Pharmaceutical Sciences, Zhengzhou University.
Int J Nanomedicine. 2017 Oct 25;12:7869-7884. doi: 10.2147/IJN.S143977. eCollection 2017.
Personalized and precise nanomedicines are highly demanded for today's medical needs. Liposomes are ideal candidates for the construction of multifunctional drug delivery systems. In this study, a liposome was used to improve the clinical issues of docetaxel (Doc), a potent antimitotic chemotherapy for prostate cancer (PC). RLT, a low-density lipoprotein receptor (LDLR)-binding peptide, and PEG were conjugated to the liposomes, and gold nanorods (GNRs) were also incorporated into the liposomes. The GNRs/Doc-liposome-RLT (GNRs/DocL-R) was tested in PC-3 cells and in PC-3 tumor-bearing nude mice. Results showed that GNRs/DocL-R possessed a diameter approximately 163.15±1.83 nm and a zeta potential approximately -32.8±2.16 mV. GNRs/DocL-R showed enhanced intracellular entrance, increased accumulation in the implanted tumor region, and the highest tumor inhibition in vitro and in vivo. Therefore, the multifunctional GNRs/DocL-R was a potential cancer treatment via combined chemo- and thermotherapy.
当今的医学需求对个性化和精准的纳米药物有很高的要求。脂质体是构建多功能药物递送系统的理想候选者。在本研究中,使用脂质体来改善多西他赛(Doc)的临床问题,多西他赛是一种用于前列腺癌(PC)的强效抗有丝分裂化疗药物。将低密度脂蛋白受体(LDLR)结合肽RLT和聚乙二醇(PEG)偶联到脂质体上,并且还将金纳米棒(GNRs)掺入脂质体中。在PC-3细胞和PC-3荷瘤裸鼠中对GNRs/Doc-脂质体-RLT(GNRs/DocL-R)进行了测试。结果表明,GNRs/DocL-R的直径约为163.15±1.83nm,zeta电位约为-32.8±2.16mV。GNRs/DocL-R显示出增强的细胞内摄取、在植入肿瘤区域的积累增加以及在体外和体内的最高肿瘤抑制作用。因此,多功能的GNRs/DocL-R通过化学疗法和热疗法的联合是一种潜在的癌症治疗方法。
Int J Nanomedicine. 2017-10-25
Colloids Surf B Biointerfaces. 2017-9-23
Mol Cancer. 2025-6-9
Int J Mol Sci. 2023-4-1
Front Pharmacol. 2022-10-17
Nanomaterials (Basel). 2022-10-21
Heliyon. 2022-5-13
Biomedicines. 2022-5-20
Adv Drug Deliv Rev. 2015-12-1
Int J Nanomedicine. 2015-8-25
Eur J Pharm Biopharm. 2015-8
Colloids Surf B Biointerfaces. 2014-11-22